Ciprofloxacin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Ciprofloxacin

Ciprofloxacin is the generic international name for the synthetic antibiotic manufactured and sold by Bayer Pharmaceutical under the brand names Cipro® and Ciproxin® (and other brand names in other markets, e.g. veterinary drugs), belonging to a group called fluoroquinolones. Ciprofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.

Activity

Ciprofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

  • Enterobacteriaceae
  • Vibrio
  • Haemophilus influenzae
  • Neisseria gonorrhoeae
  • Neisseria menigitidis
  • Moraxella catarrhalis
  • Brucella
  • Campylobacter
  • Mycobacterium intracellulare
  • Legionella sp.
  • Pseudomonas aeruginosa
  • Bacillus anthracis - that causes anthrax

Weak activity against:

  • Streptococcus pneumoniae
  • Chlamydia trachomatis
  • Chlamydia pneumoniae

No activity against:

  • Bacteroides
  • Burkholderia cepacia
  • Enterococcus faecium
  • Ureaplasma urealyticum
  • and others

The major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics. Because of its general safety, potency and broad spectrum activity, ciprofloxacin was initially reserved as a "last-resort" drug for use on difficult and drug-resistant infections. As with any antibiotic, however, increasing time and usage has led to an increase in ciprofloxacin-resistant infections, mainly in the hospital setting. Also implicated in the rise of resistant bacteria is the use of lower-cost, less potent fluoroquinolones, and the widespread addition of ciprofloxacin and other antibiotics to the feed of farm animals, which leads to greater and more rapid weight gain, for reasons which are not clear.

Label information

The drug is available for oral and parenteral use. It is used in lower respiratory infections (pneumonias), urinary tract infections, STDs, septicemias, Legionellosis and atypical Mycobacterioses. Dosage in respiratory infections is 500-1500 mg a day in 2 doses.

It is contraindicated in children, pregnancy, and in patients with epilepsy. Dose adjustment or avoidance may be necessary with liver or renal failure.

Ciprofloxacin can cause photosensitivity reactions and can elevate plasma theophylline levels to toxic values. It can also cause constipation and sensitivity to caffeine.

Interactions

Quercetin, a flavonoid occasionally used as a dietary supplement may interact with fluroquinolones, as quercetin competitively binds to bacterial DNA gyrase. Some foods such as garlic and apples contain high levels of quercetin. Whether this inhibits or enhances the effect of Fluoroquinolones is not immediately clear.

Read more at Wikipedia.org


[List your site here Free!]


3 days ciprofloxacin adequate for UTI in older women
From Journal of Family Practice, 6/1/04

Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004:170:469-4 73.

* CLINICAL QUESTION

Is 3 days of ciprofloxacin as effective as 7 to 10 days of the same drug for older women with urinary tract infection?

* BOTTOM LINE

This reasonably large study found that 3 days of ciprofloxacin (Cipro) twice daily is as effective and better tolerated than 7 days of treatment for healthy older women with urinary tract infection (UTI). Although a much larger study might find a small difference in outcomes, it is unlikely to be clinically meaningful; this study was powered to detect a modest 10% difference in outcomes. (LOE=1b)

* STUDY DESIGN

Randomized controlled trial (double-blinded)

* SETTING

Outpatient (any)

* SYNOPSIS

We know that 3 days of antibiotics is effective for uncomplicated lower UTI in young healthy women. However, most physicians still use a longer course of 7 to 10 days for older women.

In this study, women aged >65 years with a positive urine culture and at least 1 symptom of UTI were randomized to receive either oral ciprofloxacin 250 mg twice daily for 3 days plus placebo for 4 days (n=93) or ciprofloxacin 250 mg twice daily for 7 days (n=89). Women with diabetes, an indwelling catheter, abnormal renal function, sepsis, recent use of antibiotics, or signs of pyelonephritis (not specified what they are) were excluded. Groups were similar at baseline, allocation was appropriately concealed, and analysis was by intention to treat. Patients were followed up for a total of 6 weeks.

Four patients withdrew from the 7-day group because of adverse events, compared with 1 in the 3-day group. There were 2 deaths in each group (the study included some hospitalized patients, since it was organized via a central laboratory). Most had Escherichia coli (71%), and 15.8% had Klebsiella pneumoniae. There was no difference between groups at 2 days after completion of antibiotic therapy regarding bacterial eradication (98% for the 3-day group vs 93% for the 7-day group) or symptom improvement (98% for the 3-day group vs 92% for the 7-day group). The same was true at 6 weeks, with similar rates of reinfection (14% vs 18%) and relapse (15% vs 13%). Adverse effects--drowsiness, loss of appetite, and nausea or vomiting, in particular--were more common in the 7-day group.

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Ciprofloxacin
Home Contact Resources Exchange Links ebay